Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1977 May;74(5):2126–2129. doi: 10.1073/pnas.74.5.2126

L-3,4-dihydroxyphenylalanine-induced hypersensitivity simulating features of denervation.

L C Tang, G C Cotzias
PMCID: PMC431088  PMID: 266733

Abstract

The manner in which dyskinesia and intermittency of neurological control had emerged late in the therapy of Parkinsonism with L-3,4-dihydroxyphenylalanine (levodopa) had suggested to us that this drug can imprint on the brain a chemical memory of its passage. The majority of authors ascribed these events to denervation hypersensitivity caused by the nigral and other lesions of the disease. By feeding levodopa to mice, however, we induced a state that simulated denervations hypersensitivity, including hyperreaction to single injections of levodopa and increased dopamine-stimulated adenylate cyclase [ATP pyrophosphate-lyase (cyclizing), EC 4.6.1.1] activity in homogenates of caudate nuclei. These phenomena were not caused by actual denervation, because the hypersensitivity declined and disappeared some weeks after the dietary levodopa was stopped.

Full text

PDF
2126

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbeau A. The clinical physiology of side effects in long-term L-DOPA therapy. Adv Neurol. 1974;5:347–365. [PubMed] [Google Scholar]
  2. Cotzias G. C. Levodopa, manganese, and degenerations of the brain. Harvey Lect. 1974;68:115–147. [PubMed] [Google Scholar]
  3. Cotzias G. C., Miller S. T., Nicholson A. R., Jr, Maston W. H., Tang L. C. Prolongation of the life-span in mice adapted to large amounts of L-dopa. Proc Natl Acad Sci U S A. 1974 Jun;71(6):2466–2469. doi: 10.1073/pnas.71.6.2466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
  5. Cotzias G. C., Papavasiliou P. S., Steck A., Düby S. Parkinsonism and levodopa. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):319–322. doi: 10.1002/cpt1971122part2319. [DOI] [PubMed] [Google Scholar]
  6. Cotzias G. C., Papavasiliou P. S., Tolosa E. S., Mendez J. S., Bell-Midura M. Treatment of Parkinson's disease with aporphines. Possible role of growth hormone. N Engl J Med. 1976 Mar 11;294(11):567–572. doi: 10.1056/NEJM197603112941101. [DOI] [PubMed] [Google Scholar]
  7. Gale K., Guidotti A., Costa E. Dopamine-sensitive adenylate cyclase: location in substantia nigra. Science. 1977 Feb 4;195(4277):503–505. doi: 10.1126/science.13499. [DOI] [PubMed] [Google Scholar]
  8. Gilman A. G. A protein binding assay for adenosine 3':5'-cyclic monophosphate. Proc Natl Acad Sci U S A. 1970 Sep;67(1):305–312. doi: 10.1073/pnas.67.1.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Horn A. S., Cuello A. C., Miller R. J. Dopamine in the mesolimbic system of the rat brain: endogenous levels and the effects of drugs on the uptake mechanism and stimulation of adenylate cyclase activity. J Neurochem. 1974 Feb;22(2):265–270. doi: 10.1111/j.1471-4159.1974.tb11589.x. [DOI] [PubMed] [Google Scholar]
  10. Kebabian J. W., Petzold G. L., Greengard P. Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor". Proc Natl Acad Sci U S A. 1972 Aug;69(8):2145–2149. doi: 10.1073/pnas.69.8.2145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kebabian J. W., Saavedra J. M. Dopamine-sensitive adenylate cyclase occurs in a region of substantia nigra containing dopaminergic dendrites. Science. 1976 Aug 20;193(4254):683–685. doi: 10.1126/science.181842. [DOI] [PubMed] [Google Scholar]
  12. Klawans H. L., Jr The pharmacology of tardive dyskinesias. Am J Psychiatry. 1973 Jan;130(1):82–86. doi: 10.1176/ajp.130.1.82. [DOI] [PubMed] [Google Scholar]
  13. Marsden C. D., Parkes J. D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1976 Feb 7;1(7954):292–296. doi: 10.1016/s0140-6736(76)91416-1. [DOI] [PubMed] [Google Scholar]
  14. Mishra R. K., Gardner E. L., Katzman R., Makman M. H. Enhancement of dopamine-stimulated adenylate cyclase activity in rat caudate after lesions in substantia nigra: evidence for denervation supersensitivity. Proc Natl Acad Sci U S A. 1974 Oct;71(10):3883–3887. doi: 10.1073/pnas.71.10.3883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tang L. C., Cotzias G. C., Dunn M. Changing the actions of neuroactive drugs by changing brain protein synthesis. Proc Natl Acad Sci U S A. 1974 Sep;71(9):3350–3354. doi: 10.1073/pnas.71.9.3350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Tang L. C., Cotzias G. C. Modification of the actions of some neuroactive drugs by growth hormone. Arch Neurol. 1976 Feb;33(2):131–134. doi: 10.1001/archneur.1976.00500020059009. [DOI] [PubMed] [Google Scholar]
  17. Tang L. C., Cotzias G. C. Opposing effects of dopaminergic to cholinergic compounds on a cerebral dopamine-activated adenylate cyclase. Proc Natl Acad Sci U S A. 1977 Feb;74(2):769–773. doi: 10.1073/pnas.74.2.769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Tang L. C., Cotzias G. C. Quantitative correlation of dopamine-dependent adenylate cyclase with responses to levodopa in various mice. Proc Natl Acad Sci U S A. 1977 Mar;74(3):1242–1244. doi: 10.1073/pnas.74.3.1242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ungerstedt U., Arbuthnott G. W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970 Dec 18;24(3):485–493. doi: 10.1016/0006-8993(70)90187-3. [DOI] [PubMed] [Google Scholar]
  20. Von Voigtlander P. F., Boukma S. J., Johnson G. A. Dopaminergic denervation supersensitivity and dopamine stimulated adenyl cyclase activity. Neuropharmacology. 1973 Nov;12(11):1081–1086. doi: 10.1016/0028-3908(73)90052-x. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES